A Cross-sectional Study on Intradialytic Hypertension at Four Haemodialysis Units in the Western Cape
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01916668|
Recruitment Status : Completed
First Posted : August 5, 2013
Last Update Posted : May 7, 2014
|Condition or disease|
Intradialytic hypertension (IDH) is the paradoxical rise in blood pressure (BP) during or immediately after haemodialysis.
Nephrologists have yet to arrive at a standard definition of IDH. Definitions vary widely from systolic blood pressure rises of ≥ 10mmHg, rise in mean arterial pressure (MAP) during dialysis > 15mmHg to hypertension that appears resistant to ultrafiltration during or immediately after dialysis.1 Depending on the definition used, the prevalence of IDH varies between 5-15%.
This phenomenon may appear trivial to the inexperienced doctor. However, IDH increases the risk of hospitalization and death as reported in the Crit-Line Intradialytic Monitoring Benefit Study (CLIMB) and United States Renal Data System (USRDS) haemodialysis study.
The pathogenesis of IDH is unclear. A number of factors have been implicated and probably work synergistically to promote the rise in BP. These include: subclinical volume overload, activation of the sympathetic and renin-angiotensin-aldosterone systems, endothelial dysfunction, sodium gain during dialysis, use of erythropoietin stimulating agents (ESAs) and removal of anti-hypertensive agents during dialysis.
The management of IDH relies heavily on control of sodium and fluid dynamics. There are no randomized controlled studies to guide management.
Primary: Determine the prevalence of IDH at four haemodialysis units in the Western Cape
Secondary: To examine the association between IDH and the following potential risk factors:
Intradialytic weight gain, the presence and/or degree of fluid overload as assessed by bioimpedance monitoring, quantity and timing of anti-hypertensive drugs, ESA dose and route of administration, time-averaged sodium concentration, dialysate calcium concentrations and haemodialysis modality.
A multicentre, cross-sectional study on chronic haemodialysis patients at four adult dialysis units in the Western Cape will be conducted.IDH will be defined as a rise of ≥10mmHg in systolic blood pressure between pre- and post-dialysis in at least 4 out of six dialysis sessions. Patients screened as eligible for inclusion in the study will be identified from haemodialysis charts by the primary investigator (PI). They will then be approached by the PI, who will try to obtain informed consent. Once informed consent has been obtained and no exclusion criteria are present, the patient will be enrolled. A study ID number will be allocated.
Using a standard operating protocol (SOP), weight, BP, pulse rate, bioimpedance, ultrafiltration rates and volumes will be determined before, hourly during dialysis and 30 minutes after completion of dialysis. Timing and use of antihypertensive drugs, ESA use, dialysis modality, intradialytic calcium and time averaged sodium levels will be determined. All data extracted will be captured onto a standardised data sheet.
|Study Type :||Observational|
|Actual Enrollment :||200 participants|
|Official Title:||A Cross-sectional Study on Intradialytic Hypertension at Four Haemodialysis Units in the Western Cape, South Africa|
|Study Start Date :||April 2013|
|Actual Primary Completion Date :||April 2014|
|Actual Study Completion Date :||May 2014|
- Prevalence of intradialytic hypertension at four haemodialysis units in the Western Cape [ Time Frame: Up to 1 year ]
- Participants pre- and post hemodialysis bioimpedance measurements [ Time Frame: Up to 1 year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01916668
|Tygerberg Academic Hospital|
|Cape Town, Western Cape, South Africa, 7505|
|Principal Investigator:||Mogamat-Yazied Dr Chothia, FCP(SA)||University of Stellenbosch|